卡培他滨联合替莫唑胺治疗晚期胰腺神经内分泌肿瘤的临床观察

刘青; 张盼; 罗杰; 窦豆; 谭煌英

doi:10.3969/j.issn.1000-8179.2017.05.404

卡培他滨联合替莫唑胺治疗晚期胰腺神经内分泌肿瘤的临床观察

Clinical observation of capecitabine and temozolomide in the treatment of advanced pancreatic neuroendocrine tumors

摘要

摘要:
目的观察卡培他滨联合替莫唑胺治疗晚期胰腺神经内分泌肿瘤（pancreatic neuroendocrine neoplasm，pNENs）的疗效及不良反应。
方法回顾性分析2014年2月至2016年10月中日友好医院收治的14例经病理学确诊，分化良好的Ⅳ期pNENs患者，接受口服CAPTEM方案，分析治疗后的无进展生存期（progression free survival，PFS）及不良反应。
结果 14例患者接受定期随访2年余（2014年1月至2016年10月），1例完全缓解（complete resporse，CR），1例部分缓解（partial response，PR），4例疾病稳定（stable disease，SD），中位无进展生存期（median progression free survival，mPFS）约为8.9（3~24）个月，2年生存率为85.7%（12/14），其中不良反应均为3级以下的骨髓抑制、消化道反应。
结论卡培他滨联合替莫唑胺（capecitabine and temozolomide，CAPTEM）方案是治疗晚期胰腺神经内分泌瘤（pancreatic neuroendocrine tumor，pNET）的有效化疗方案，患者耐受性较好。

Abstract:
Objective To observe the therapeutic effect and toxicity of capecitabine and temozolomide in the treatment of advanced pancreatic neuroendocrine tumors.
Methods A total of 14 patients with stage Ⅳ well-differentiated pancreatic neuroendocrine tumor (NET G₁/G₂/G₃) were treated with oral CAPTEM regimen, and the response rate, PFS and adverse effect after treatment were analyzed. All data analyses were performed using software SPSS17.0.
Results These 14 patients were followed-up for more than 2 years. Till Oct 2016, one patient got CR, one patient got PR, four patients got SD. Median progression-free survival was 8.9 months. The two year survival rate was 85.7%. Only one patient experienced grade 3 adverse events.
Conclusion CAPTEM is an effective and well-tolerated salvage regimen for the treatment of advanced well-differentiated pNET.

HTML全文

参考文献(17)

施引文献

资源附件(0)